Sihuan Pharmaceutical (00460.HK): Subsidiary Huisheng Biopharmaceutical Reshapes Diabetes Treatment Landscape With Two Home-Grown Insulin Products

EQS Newswire / 21/08/2024 / 10:07 UTC+8 1. With Two Home-Grown Insulin Products Approved for Marketing, It Leads the Development of The Domestic Insulin MarketOn August 6th, Sihuan Pharmaceutical (00460.HK) announced that Insulin Degludec and Insulin Aspart Injection (trade name: Huiyoujia), developed by its subsidiary Huisheng Biopharmaceutical, was approved for…